All In Biotech

Drug Trial Radar · NCT04847440

A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

A Phase 2A Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose Ranging Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

Last checked: Nov 19, 2026Latest source record: Nov 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

40

Actual

Start

Mar 30, 2021

Primary completion

Sep 1, 2022

Study completion Sep 1, 2022

Sponsor

Lead sponsor
Antios Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Apr 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in both volunteers with chronic hepatitis B virus infection and in volunteers with hepatitis D virus coinfection. Volunteers will be administered multiple oral doses of ATI-2173 and assessed for safety and efficacy including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the drug effects the virus infection.

Conditions

  • Hepatitis B, Chronic
  • Hepatitis D

Interventions

  • ATI-2173Drug

    ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.

  • VireadDrug

    Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.

  • AB-729Drug

    AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of subjects who experienced at least 1 treatment-emergent adverse event (TEAE)Time frame: Through study completion, an average of 1 year
  2. The percentage of subjects who experienced at least one treatment emergent serious AE (SAE).Time frame: Through study completion, an average of 1 year
  3. Percentage of subjects who experienced a treatment-emergent dose limiting toxicity (DLT)Time frame: Through study completion, an average of 1 year
  4. Percentage of subjects who experienced at least one treatment emergent Grade 1, 2, 3, 4 or 5 laboratory abnormalityTime frame: Through study completion, an average of 1 year
  5. Percentage of subjects who discontinued study drug due to a TEAETime frame: Through study completion, an average of 1 year
  6. Alanine aminotransferase and aspartate aminotransferase levels versus timeTime frame: Through study completion, an average of 1 year
  7. Time to HBV viral load relapse in HBV-infected subjectsTime frame: Through study completion, an average of 1 year
  8. The reduction of HDV RNA on-treatment for HBV/HDV coinfected subjectsTime frame: Through study completion, an average of 1 year

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Republican Clinical Hospital "Timofei Mosneaga" Arensia EM Unit

    Chisinau, Republic of Moldova, Moldova

  • Medical Center of Limited Liability Company "Harmoniya krasy"

    Kyiv, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.